Aequus Pharmaceuticals, Inc.

VANCOUVER, September 22nd, 2025 – Aequus Pharmaceuticals Inc. (TSX-V: AQS) (“Aequus” or the “Company”), a specialty pharmaceutical company focused on bringing healthcare solutions to Canadians through licensing and partnerships, is pleased to announce Giovanni Di Genova has agreed to join the Aequus Board of Directors, subject to the completion of his PIF and TSX approval, effective Friday September 12th, 2025. “Aequus is pleased to welcome Giovanni Di Genova as a new director and we are eager to work with him on the future ahead.” Said Doug Janzen, Aequus Chairman & CEO. ABOUT GIOVANNI DI GENOVA Giovanni Di Genova earned his Bachelor of Science and Bachelor of Pharmacy from McGill University and Université de Montréal, respectively. He began his career in the specialty compounding pharmacy & pharmaceutical industry nearly 35 years ago, covering multiple therapeutic areas including ophthalmology, oncology, gastrointestinal, neurological, infectious, and autoimmune diseases. John has held positions in both innovative and generic pharmaceutical organizations, with roles in API/Materials Management, Production, Sales, Marketing and Business Development. He has a proven track record in strategy and operations, including strong business development experience with M&A, licensing, co-development, and supply agreements. John started his career at Ayerst and PharmaScience, and most recently, served as CEO and founder of Advanced Dosage Forms, a private firm involved in the licensing, sales, marketing, and distribution of high-barrier-to-market niche pharmaceuticals. ABOUT AEQUUS PHARMACEUTICALS INC. Aequus Pharmaceuticals Inc. (TSX-V: AQS) is a specialty pharmaceutical company, with a focus on commercializing value-added products in specialty therapeutic areas in the Canadian market. ‍

VANCOUVER, May 23rd, 2025 – TheNewswire - Aequus Pharmaceuticals Inc. (TSX-V: AQS) (“Aequus” or the “Company”), a specialty pharmaceutical company focused on bringing healthcare solutions to Canadians through licensing and partnerships, and Luvo Medical Technologies Inc. (“Luvo”), today announce the signing of an Asset Purchase Agreement for the sale of Zimed® PF (the “Transaction”). Unless otherwise noted, all figures are in Canadian currency. “Since Zimed® PF was launched in 2023 in collaboration with Medicom Healthcare Ltd, we’ve been pleased with the positive impact it has had with Canadian Ophthalmologists and their patients. This transaction with Luvo will ensure consistent product supply to Canadians while significantly improving Aequus’ financial outlook. We look forward to working with the Luvo team on transitioning Zimed® PF operations. Aequus will be actively seeking opportunities to use the remaining company in strategic partnerships, or to pursue other future endeavors” said Doug Janzen, CEO of Aequus. Under the terms of the agreement, Luvo will pay Aequus a lump sum payment of $400,000 at the closing of the transaction and an ongoing royalty of 6% on gross profit attributable to the sale of Zimed PF® (less certain costs and fees) until July 29th, 2029. Until closing, Luvo will be responsible for managing distribution and commercialization efforts of Zimed® PF. If existing inventory is not depleted by closing, Luvo will purchase the outstanding inventory. The Transaction is expected to close in Q4 2025 upon the transfer of the Drug Identification Number (DIN) and is subject to certain closing conditions, including TSX Venture Exchange and shareholder approval. Aequus expects to call a special meeting of shareholders to be held in Q3 2025 for approval of the Transaction. There is no guarantee that the Transaction will close on the terms set forth herein or at all. If, following closing of the Transaction, a future strategic partnership or other transaction is not available, Aequus may pursue other alternatives including a potential wind-up of operations. ABOUT LUVO MEDICAL TECHNOLOGIES INC. Luvo Medical Technologies Inc. is a subsidiary of Clarion Medical Technologies Inc., a leading Canadian provider of medical equipment and consumables to aesthetic and vision providers in private clinics and hospitals. ABOUT MEDICOM HEALTHCARE LTD Medicom Healthcare Ltd is a UK-based specialty pharmaceutical company with a global presence specialising in high quality eyecare products designed to protect the cornea and treat dry eye syndrome, blepharitis and glaucoma. ABOUT AEQUUS PHARMACEUTICALS INC. Aequus Pharmaceuticals Inc. (TSX-V: AQS) is a specialty pharmaceutical company, with a focus on commercializing value-added products in specialty therapeutic areas in the Canadian market.

VANCOUVER, BC. July 3rd – Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB:AQSZF), (“Aequus” or the “Company”), a specialty pharmaceutical company, announces the highest selling quarter since the launch of Zimed® PF (Bimatoprost 0.03%), the first and only multi-dose preservative free prostaglandin analog (PGA) in Canada. “With continued momentum, we are pleased to see that June was another record month of sales for Zimed® PF” says Doug Janzen, CEO of Aequus Pharmaceuticals Canada. “It’s encouraging to see clinicians integrating it into their practices and see the value preservative free alternatives can bring to their patients”. For more information, please visit www.ZimedPF.ca About Aequus Pharmaceuticals Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus, founded in 2015, has successfully grown multiple products and brands in strategic therapeutic areas including Ophthalmology, Optometry, Transplant and Rare Disease. Aequus plans to build on its Canadian commercial platform through the application of sales, marketing and expert knowledge of the Canadian marketplace utilizing internal development, acquisition, or licenses with preferred strategic partners. For further information, please visit www.aequuspharma.ca. About Glaucoma, Dry Eye and Zimed® PF Zimed®PF is indicated for the reduction of elevated intraocular pressure (IOP) inpatients with open-angle glaucoma or ocular hypertension. Glaucoma and elevated intraocular pressure can cause vision loss or blindness by damaging the optic nerve located at the back of the eye. Dry eye disease is often associated with glaucoma due to factors including age, environment, allergies, and preservatives in eyedrops. Zimed® PF is the first multi-dose preservative free prostaglandin analog (PGA) available in Canada. Zimed®PF (bimatoprost 0.03%) received market authorization from Health Canada in December 2022.